JHVEPhoto When I last wrote about the pharmaceuticals company Bristol-Myers Squibb (NYSE:BMY) in June, there appeared little impetus for a price uptick. The company had made a shock earnings outlook downgrade for 2024 following massive acquisition related charges, resulting in an impossibly high forward non-GAAP price-to-earnings (P/E) ratio for the year. This meant that before a re-normalisation of its EPS in 2025, there was little else foreseeable that could surprise about BMY. I was wrong. The stock ...

John Scott/DigitalVision via Getty ImagesDespite lingering skepticism about Bristol-Myers Squibb's future (NYSE:BMY) on Wall Street in recent months, fueled by investor concerns about Eliquis facing patent expirations in 2026, the company pleasantly surprised me with its second-quarter financial results, thanks in part to strong sales in its cardiovascular franchise that offset a muted 11% year-over-year sales growth in its blockbuster PD-1 inhibitor Opdivo due to increasing competition from Merck's Key ...

From a technical perspective, Bristol Myers Squibb (BMY) is looking like an interesting pick, as it just reached a key level of support. BMY recently overtook the 200-day moving average, and this suggests a long-term bullish trend.A useful tool for traders and analysts, the 200-day simple moving average helps determine long-term market trends for stocks, commodities, indexes, and other financial instruments. It moves higher or lower in conjunction with longer-term price performance, and serves as a support ...

gawrav Buying headline-making growth stocks can be fun while they are on their way up. But with so many eyeballs on those names, one has to wonder whether if all the positivity is already baked into the share price, as may be the case with NVIDIA (NVDA) at today’s prices. While it’s great to see a ton of growth in year 1, what if years 2-10 are followed by mediocre returns? Moreover, too high a share price combined with a low dividend yield makes for inadequate return potential through dividend reinvest ...

One of the most pertinent drivers of the stock market that is often not considered by many investors is the demographic trajectory of the U.S. Currently, the U.S. population is older than ever before in history. For example, between 1980 and 2022, the median age of the American population increased from 30.0 to 38.9. Almost no market sector will feel the impact of America’s aging population more than healthcare. As a result, healthcare stocks are likely to soar in the next decade.However, only specific heal ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our ...

A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program.If you're looking for a way to permanently boost your passive income stream, you've probably seen Bristol Myers Squibb (BMY -2.91%) when you screen for stocks that pay big dividends.At recent prices, the Big Pharma stock offers a 4.7% yield. Unfortunately, dividend payers rarely offer such high yields unless there are reasons to suspect they can't maintain their payout-raisi ...

JHVEPhoto/iStock Editorial via Getty Images Bristol-Myers Squibb Company (NYSE:BMY) crossed $50 / share after a double-digit share price increase on the back of strong earnings. We recently discussed the company, highlighting how shareholders are too focused on the long term instead of celebrating its strength today. The company's recent Q2 earnings highlight how it can drive immediate and strong shareholder returns. Bristol-Myers Squibb 2Q 2024 Performance The company has achieved strong 2Q 2024 perfor ...

Bristol-Myers Squibb Co BMY on Friday reported upbeat second-quarter results.The report came amid an exciting earnings season. Here are some key analyst takeaways.Barclays On Bristol-Myers SquibbAnalyst Carter Gould downgraded the rating to Underweight, while maintaining the price target at $41.Gould explained the downgrade, stating that the recent rally in Bristol-Myers Squibb’s stock, “despite little movement in underlying post-2025 fundamentals,” appears to be “an over-reaction to the IRA news.”The compa ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Barclays analyst Carter Gould downgraded the rating for Bristol-Myers Squibb Company BMY from Equal-Weight to Underweight and maintained the price target of $41. Bristol-Myers Squibb shares gained 11.4% to settle at $50.45 on Friday. See how other analysts view this stock. See how other analysts view this sto ...